Drugs / Blosozumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02337387 | Jan → Mar 2015 | postmenopausal osteoporosis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT02109042 | Apr → Jul 2014 | postmenopausal osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01742091 | Sep 2009 → Mar 2010 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01742078 | Jun 2008 → Jun 2010 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01144377 | Aug 2010 → May 2012 | osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blosozumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02109042 ↗ |
| Known as | LY2541546 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01144377 ↗ |
| Action | Inhibit | “Sclerostin inhibitor” CHEMBL1742993 ↗ |
| Modality | Monoclonal antibody | — CHEMBL1742993 ↗ |
| Route | Subcutaneous | “Administered subcutaneously” NCT01144377 ↗ |
| Target | SOST | “Sclerostin inhibitor” CHEMBL1742993 ↗ |